| pmol ⋅ mg protein−1 ⋅ min−1 | μM | |
Control | 1095 ± 269 | 22.3 ± 2.4 | |
Probenecid (15 μM) | 897 ± 233 | 42.0 ± 4.8a | Competitive |
Control | 1095 ± 172 | 14.8 ± 2.1 | |
Cidofovir (100 μM) | 1388 ± 373 | 50.1 ± 17.6a | Competitive |
Control | 759 ± 88.0 | 14.5 ± 1.1 | |
Ibuprofen (5 μM) | 1057 ± 93.8 | 49.3 ± 5.4b | Competitive |
Control | 632 ± 80.4 | 15.1 ± 2.8 | |
Estrone-3-sulfate (250 μM) | 620 ± 78.6 | 57.9 ± 9.5a | Competitive |
Control | 939 ± 145 | 21.9 ± 3.9 | |
Indomethacin (5 μM) | 921 ± 174 | 51.3 ± 15a | Competitive |
Control | 733 ± 133 | 19.0 ± 2.2 | |
Furosemide (30 μM) | 710 ± 138 | 38.5 ± 5.0a | Competitive |
Control | 762 ± 147 | 19.2 ± 2.0 | |
Morin (15 μM) | 684 ± 113 | 72.5 ± 6.8b | Competitive |
Control | 945 ± 20.9 | 17.6 ± 3.4 | |
Pravastatin (1000 μM) | 1043 ± 130 | 48.8 ± 13.8c | Competitive |
Control | 828 ± 81.2 | 14.8 ± 1.5 | |
Valsartan (15 μM) | 637 ± 138 | 39.7 ± 6.8a | Competitive |
Control | 721 ± 113 | 13.3 ± 0.95 | |
Olmesartan (15 μM) | 801 ± 114 | 77.6 ± 12b | Competitive |
Control | 518 ± 42.1 | 29.6 ± 6.1 | |
Telmisartan (0.5 μM) | 121 ± 9.1b | 37.3 ± 6.9 | Noncompetitive |
Control | 1083 ± 71.7 | 17.3 ± 2.7 | |
Azilsartan (15 μM) | 833 ± 68.2c | 27 ± 5.3 | Noncompetitive |
Control | 933 ± 76.9 | 16.8 ± 2.7 | |
Irbesartan (10 μM) | 574 ± 65.8c | 31.8 ± 5.3c | Mixed-type |
Control | 921 ± 60.4 | 15.5 ± 1.5 | |
Omeprazole (20 μM) | 698 ± 47.7c | 37.0 ± 3.8b | Mixed-type |